GSTM1 and chronic kidney disease: In the anemic patients with DD-CKD, 59.1%, 88.9% (P = 0.008) and 100% (P = 0.0003) of the low-, medium- and high-dose subjects maintained their Hb levels versus 50% of the epoetin alfa-treated subjects (Chen et al., 2017).